Rapid desensitisation for desferrioxamine anaphylactic reaction
- PMID: 6112440
- DOI: 10.1016/s0140-6736(81)92227-3
Rapid desensitisation for desferrioxamine anaphylactic reaction
Similar articles
-
Rapid desensitisation for desferrioxamine anaphylactoid reaction.Lancet. 1983 Oct 8;2(8354):859-60. doi: 10.1016/s0140-6736(83)90785-7. Lancet. 1983. PMID: 6137689 No abstract available.
-
Modified desensitization protocols for a pediatric patient with anaphylactic reaction to deferoxamine.J Med Assoc Thai. 2014 Aug;97 Suppl 8:S217-22. J Med Assoc Thai. 2014. PMID: 25518318
-
Anaphylactic reaction to desferrioxamine.Lancet. 1977 Sep 17;2(8038):616. doi: 10.1016/s0140-6736(77)91473-8. Lancet. 1977. PMID: 71438 No abstract available.
-
Allergy to monoclonal antibodies: cutting-edge desensitization methods for cutting-edge therapies.Expert Rev Clin Immunol. 2012 Jan;8(1):43-52; quiz 53-4. doi: 10.1586/eci.11.75. Expert Rev Clin Immunol. 2012. PMID: 22149339 Review.
-
Utility of desensitisation for allergy to antibiotics.Neth J Med. 2012 Mar;70(2):58-62. Neth J Med. 2012. PMID: 22418750 Review.
Cited by
-
High dosage desferrioxamine therapy in a female patient with acquired aplastic anaemia and transfusion siderosis.Blut. 1986 Apr;52(4):211-9. doi: 10.1007/BF00321080. Blut. 1986. PMID: 3634632
-
Desferrioxamine mesylate for managing transfusional iron overload in people with transfusion-dependent thalassaemia.Cochrane Database Syst Rev. 2013 Aug 21;2013(8):CD004450. doi: 10.1002/14651858.CD004450.pub3. Cochrane Database Syst Rev. 2013. PMID: 23963793 Free PMC article.
-
A risk-benefit assessment of iron-chelation therapy.Drug Saf. 1997 Dec;17(6):407-21. doi: 10.2165/00002018-199717060-00006. Drug Saf. 1997. PMID: 9429839 Review.
-
The Importance and Essentiality of Natural and Synthetic Chelators in Medicine: Increased Prospects for the Effective Treatment of Iron Overload and Iron Deficiency.Int J Mol Sci. 2024 Apr 25;25(9):4654. doi: 10.3390/ijms25094654. Int J Mol Sci. 2024. PMID: 38731873 Free PMC article. Review.
-
Benefits and risks of deferiprone in iron overload in Thalassaemia and other conditions: comparison of epidemiological and therapeutic aspects with deferoxamine.Drug Saf. 2003;26(8):553-84. doi: 10.2165/00002018-200326080-00003. Drug Saf. 2003. PMID: 12825969 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical